LY2784544

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Essential ThrombocythemiaMyelofibrosisMyeloproliferative DisordersMyeloproliferative Neoplasms ofPolycythemia VeraPrimary MyelofibrosisThrombocythemia, Essential

Phase 1

A Study in Myeloproliferative Disorders

CompletedNCT01134120

Eli Lilly and CompanyMyeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis +1

Start: 2010-04-30End: 2018-02-22Target: 80Updated: 2018-04-17

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

CompletedNCT01520220

Eli Lilly and CompanyEssential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms of +1

Start: 2012-06-11End: 2017-02-24Updated: 2017-04-12

Related Papers

A phase 1 study of the Janus kinase 2 (JAK2)<sup>V617F</sup> inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

2017-08-3129 citations

Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)

Blood2013-11-1524 citations